Second- and third-generation ALK inhibitors for non-small cell lung cancer

Wu, Jingjing; Savooji, John; Liu, Delong

doi:10.1186/s13045-016-0251-8

Cited by 121 publications

(96 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tyrosine kinase inhibitors (TKIs) targeting EGFR and ALK have been widely used to treat NSCLC, but frequent resistance to these drugs develops due to acquired mutations of EGFR [5][6][7] and of ALK. 8 Furthermore, recently introduced CTLA4, PD-1 and PD-L1 immune checkpoint inhibitors have had no 9 or only moderate effects on NSCLC. [10][11][12][13] Therefore, novel treatment regimens are still needed.…”

Section: Introductionmentioning

confidence: 99%

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

Wei

Lai

et al. 2017

OncoImmunology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

Wei

Lai

et al. 2017

OncoImmunology

View full text Add to dashboard Cite

“…Therefore, during the last decade more potent and structurally different inhibitors have been developed (38,39). Since the development of second-generation ALK-inhibitors, which were demonstrated to be effective in crizotinib-resistant patients, are not available in China, the continuation of crizotinib plus local treatment may be a feasible option to maximize the overall clinical benefits for patients with local-site progression post crizotinib.…”

Section: Discussionmentioning

confidence: 99%

A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Jin

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract.Crizotinib is an anti-cancer drug with a substantial beneficial effect in advanced non-small-cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangement. However, the real-world data currently available on this drug are limited. Thus, the present study aimed to retrospectively examine the treatment patterns and survival outcome of 83 advanced NSCLC patients with ALK rearrangement in a single center in China. Of the 83 patients enrolled, 33 (39.8%) patients received crizotinib and the remaining 50 (60.2%) patients received chemotherapy as the initial therapy. The first-line use of crizotinib prolonged the PFS1 (progression-free survival to the first detection of subsequent disease progression) compared with chemotherapy (median, 18.5 vs. 4.9 months; P<0.001), however, it did not prolong the overall survival (OS; P= 0.802). At the last follow up, 71 (85.5%) patients had received crizotinib and 12 (14.5%) patients were crizotinib-naive. Patients who had received crizotinib exhibited a significantly longer OS as compared with those who were crizotinib-naive [hazard ratio (HR) for mortality, 0.279; 95% confidence interval, 0.107-0.727; P<0.05). Among the 71 patients who had received crizotinib, this was administered as a first-line therapy in 33 (46.5%) cases, as a second-line therapy in 22 (31.0%) cases and after the second-line therapy in 16 (22.5%) cases. No significant difference in the OS among the three groups was observed (P=0.577). The Cox multivariate analysis identified the following independent negative prognostic factors for OS: Smoking history (HR=4.565), liver invasion at diagnosis (HR=4.294) and bone invasion at diagnosis (HR=2.587). In addition, the use of crizotinib (HR= 0.319) was identified as a positive prognostic factor for OS. In conclusion, the present real-world study revealed that the use of crizotinib improved the long-term survival of patients with ALK-positive advanced NSCLC. There was no difference in survival outcome between patients with initial use of crizotinib and those with subsequent use of crizotinib after first-line therapy.

show abstract

“…Particularly, there were two mechanisms noticed in about 33% of patients who developed the secondary point mutation after treatment with crizotinib. Several point mutations were detected including G1269A, F1174L, L1152R, S1206Y, 1151Tins, I1171T, D1203N, V1180L, C1156Y, F1164V, G1202R, G1269S 22 . The most common of these mutations are L1196M and G1269A 23 .…”

Section: First Generation Of Alk Inhibitorsmentioning

confidence: 99%

Importance of Anaplastic Lymphoma Kinase Gene Re-arrangements on Non-Small Cell Lung Cancer

Nursal

2017

Kafkas J Med Sci

View full text Add to dashboard Cite

show abstract

Second- and third-generation ALK inhibitors for non-small cell lung cancer

Cited by 121 publications

References 93 publications

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Importance of Anaplastic Lymphoma Kinase Gene Re-arrangements on Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About